What clinical studies show penile traction devices increase erect penile length?
Executive summary
Randomized trials and multiple clinical series report that penile traction devices (PTDs) produce modest, statistically significant gains in penile length—most commonly measured as stretched penile length (SPL) or flaccid length—across men with Peyronie’s disease and in post‑prostatectomy patients, but direct evidence specifically documenting increases in erect penile length is sparse and indirect in many reports [1] [2] [3] [4] [5]. The highest‑quality RCT evidence centers on the RestoreX device, which showed clinically meaningful SPL gains at 3–6 months, while older cohort studies and meta‑analyses support modest lengthening but underline methodological limits and variable outcomes [1] [2] [6] [5].
1. What the randomized trials actually measured and found
A randomized, single‑blind trial of the RestoreX traction device in men with Peyronie’s disease reported a mean penile length improvement of about 1.5 cm versus 0 cm in controls at three months, and also recorded improved curvature and erectile function, with treatment prescribed 30–90 minutes daily [1] [7]. A separate single‑center randomized trial in men after radical prostatectomy found that RestoreX users had greater preservation or improvement in stretched penile length at six months (+1.6 cm vs +0.3 cm for controls) and better erectile function scores, outcomes that the authors present as both statistically and clinically significant [2] [8].
2. Older clinical series and what they reported about flaccid and stretched length
Before RestoreX, smaller prospective trials and cohort studies—such as the Golden Erect/penile‑extender series—reported increases in flaccid and stretched penile measurements: one preliminary study of 23 men found mean flaccid length increased from 8.8 cm to 10.5 cm over three months and stretched length rose from 11.5 cm to 13.2 cm, changes described as statistically significant [3]. A longer Italian study of an Andro‑Penis extender reported up to a 32% flaccid length increase and erectile function improvement over 6–12 months, though it relied on cohort methodology and longer daily wear times [4].
3. Systematic reviews and meta‑analyses: pooled signal but caveats
A recent systematic review and meta‑analysis of PTDs in Peyronie’s disease pooled randomized and cohort data and concluded that PTDs can improve penile length and curvature, but the authors emphasized heterogeneity in devices, protocols, outcome measures and follow‑up, and called for more RCTs with longer follow‑up [5]. Contemporary narrative reviews similarly position PTD as a “viable therapy to modestly improve penile length” while warning that outcomes vary by disease phase, device, and adherence [9] [10].
4. The crucial difference between stretched/flaccid length and erect length
Most clinical studies report stretched penile length (SPL) or flaccid length as primary objective measures; erect penile length is seldom the primary endpoint, so direct, repeated measures of erect length are limited in the literature, meaning claims that PTDs increase erect length are usually inferred from SPL/flaccid gains rather than from consistent erect measurements across trials [1] [3] [5]. Several trials do report improvements in erectile function scores alongside length gains, but better erections do not automatically translate into verified erect‑length increases in the peer‑reviewed data provided [2] [1].
5. Safety, compliance, conflicts and the bottom line
Across trials PTDs were generally described as safe with few serious adverse events when used as directed, but efficacy depends heavily on device, daily wear time and patient adherence, and many studies suffer from small sizes, short follow‑up, or developer‑linked conflicts of interest (for example, inventor involvement and device provision noted in RestoreX reports) which readers should weigh when interpreting results [6] [8] [2]. The balanced conclusion from the clinical literature is that PTDs can produce modest, reproducible increases in stretched and flaccid penile length—and some RCTs report preserved or improved erectile function—but direct evidence that PTDs reliably increase erect penile length across populations remains limited and largely inferential [1] [5] [3].